Furthermore, large scale experimental and clinical trials are critical to test whether combined targeting of complement at the level of C5a–C5aR1 and the GCS-glycosphingolipid pathway can affect the disease severity and/or death in patients with COVID-19 and in GD patients with COVID-19. The gene discussed is UGCG; the disease is COVID-19.